

Alprostadil (Prostaglandin E₁)

Newborn use only

2019

Alert	1 microgram = 1000 nanograms.								
Indication	For temporary maintenance of ductus arteriosus patency until corrective or palliative surgery can be performed in neonates with ductal-dependent congenital heart defects.								
Action	Relaxes the ductus arteriosus in early postnatal life and supports its patency.								
Drug Type	Prostaglandin E ₁ or PGE ₁								
Trade Name	Prostin VR.								
Presentation	Ampoules (sterile solution) 500 microgram/mL 1 mL								
Dosage / Interval	<p>Starting Dose Dose: 10 nanogram/kg/minute (range: 5 to 50 nanogram/kg/minute).</p> <p>For known congenital heart disease patients and prior to ductal closure: Start at 10 nanogram/kg/min.</p> <p>If there is no clinical or echocardiographic response to the maximum dose of 50 nanogram/kg/min, then consult a paediatric cardiologist. Very rarely they may suggest a very short trial of up to 100 nanogram/kg/min.</p> <p>Maintenance Dose 3-20 nanogram/kg/minute. Aim is to be on the lowest dose that safely maintains ductal patency.</p>								
Maximum dose	Higher doses ≥ 50 nanogram/kg/minute may be needed to resuscitate infants with poor perfusion and oxygenation ('grey baby') and with ductal closure in suspected duct-dependent congenital heart disease.								
Route	Continuous IV infusion.								
Preparation/Dilution	<p>LOW concentration continuous IV infusion [use if attempting to avoid ventilation and keep ductus open]</p> <table border="1" style="width: 100%;"> <thead> <tr> <th style="width: 50%;">Infusion strength</th> <th style="width: 50%;">Prescribed amount</th> </tr> </thead> <tbody> <tr> <td>1 mL/hour = 10 nanogram/kg/minute</td> <td>30 microgram/kg alprostadil (Prostin VR, PGE₁) and make up to 50 mL</td> </tr> </tbody> </table> <p>First dilution: Draw up 1 mL (500 microgram) of alprostadil and add 9 mL of sodium chloride 0.9% or glucose 5% to make a final volume of 10 mL with a concentration of 50 microgram/mL. Second dilution: From this, draw up 0.6 mL/kg (30 microgram/kg) and dilute to 50 mL with sodium chloride 0.9% or glucose 5%. Infuse at rate of 1 mL/h = 10 nanogram/kg/minute.</p> <p>HIGH concentration continuous IV infusion [consider if ductus closed and/or mechanically ventilated]</p> <table border="1" style="width: 100%;"> <thead> <tr> <th style="width: 50%;">Infusion strength</th> <th style="width: 50%;">Prescribed amount</th> </tr> </thead> <tbody> <tr> <td>1 mL/hour = 50 nanogram/kg/minute</td> <td>150 microgram/kg alprostadil (Prostin VR, PGE₁) and make up to 50 mL</td> </tr> </tbody> </table> <p>First dilution: Draw up 1 mL (500 microgram of alprostadil) and add 9 mL of sodium chloride 0.9% or glucose 5% to make a final volume of 10 mL with a concentration of 50 microgram/mL. Second dilution: From this, draw up 3 mL/kg (150 microgram/kg) and dilute to 50 mL with sodium chloride 0.9% or glucose 5%. Infusing at rate of 1 mL/h = 50 nanogram/kg/minute.</p>	Infusion strength	Prescribed amount	1 mL/hour = 10 nanogram/kg/minute	30 microgram/kg alprostadil (Prostin VR, PGE ₁) and make up to 50 mL	Infusion strength	Prescribed amount	1 mL/hour = 50 nanogram/kg/minute	150 microgram/kg alprostadil (Prostin VR, PGE ₁) and make up to 50 mL
Infusion strength	Prescribed amount								
1 mL/hour = 10 nanogram/kg/minute	30 microgram/kg alprostadil (Prostin VR, PGE ₁) and make up to 50 mL								
Infusion strength	Prescribed amount								
1 mL/hour = 50 nanogram/kg/minute	150 microgram/kg alprostadil (Prostin VR, PGE ₁) and make up to 50 mL								
Administration	Continuous intravenous infusion. Ensure reliable intravenous access as short half-life.								
Monitoring	Continuous pulse oximetry, heart rate, ECG and blood pressure monitoring. Assess urine output and peripheral perfusion frequently.								
Contraindications									
Precautions	Ensure adequate cardiorespiratory monitoring and cardiorespiratory resuscitation equipment available for immediate use if necessary. Apnoea is frequent. Commencement of alprostadil ≤ 20 nanogram/kg/min and low maintenance dose reduces apnoea incidence. Titrate to infant's response (increased oxygenation, echo findings and side effects) - Aim is to be on the lowest dose that safely maintains the ductal patency.								

Alprostadil (Prostaglandin E₁)

Newborn use only

2019

	Hyperosmolar – infuse at concentrations < 20 microgram/mL. Neonates with total anomalous pulmonary venous return below the diaphragm – may precipitate pulmonary oedema because of increased pulmonary blood flow.
Drug Interactions	Concomitant administration with heparin may result in an increased risk of bleeding.
Adverse Reactions	Apnoea is frequent. Commencement of alprostadil ≤ 20 nanogram/kg/min and low maintenance dose reduces apnea incidence. Methylxanthines (caffeine or aminophylline) may be used to prevent or treat apnoea. [4] May lower blood pressure by relaxing the vascular smooth muscle causing vasodilatation and can elevate body temperature. Other reported effects include abdominal distension, bradycardia, enterocolitis, vomiting and skin rash. [5] With prolonged use, skeletal changes [10] and hypertrophic pyloric stenosis [11, 12] have been reported. Extravasation may cause tissue necrosis.
Compatibility	Fluids: Glucose 5%, sodium chloride 0.9%. Y-site: Amino acid solutions, ampicillin; cefazolin; cefotaxime; chlorothiazide; dobutamine; dopamine; fentanyl; gentamicin; methylprednisolone; nitroprusside; potassium chloride; tobramycin, vancomycin; vecuronium. Syringe: Caffeine; dobutamine; dopamine; adrenaline (epinephrine); fentanyl; midazolam; morphine.
Incompatibility	Y-site: Levofloxacin
Stability	Diluted solution stable for up to 24 hours.
Storage	Ampoule: Store at 2 to 8°C. Do not freeze.
Special Comments	Do not use if cloudy (crystallised). Undiluted solution (500 microgram/mL) is hyperosmolar. Dilute before administration to a concentration of 20 microgram/mL or less.
Evidence summary	Refer to full version.
References	Refer to full version.

Original version Date: 23/06/2016	Author: ANMF Consensus Group
Current Version number: 1.1	Current Version Date: 27/06/2019
Risk Rating: Medium	Due for Review: 27/06/2022
Approval by: As per Local policy	Approval Date: